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Abstract 
Anemia is common amongst patients undergoing percutaneous coronary intervention (PCI) 
and current guidelines fail to offer recommendations for its management.   This review aims 
to examine the relationship between baseline anemia and mortality, Major Adverse 
Cardiovascular Events (MACE) and major bleeding in patients undergoing PCI.  We 
searched MEDLINE and EMBASE for studies that evaluated mortality and adverse outcomes 
in anemic and non-anemic patients who underwent PCI. Data were collected on study design, 
participant characteristics, definition of anemia, follow up and adverse outcomes.  Random 
effects meta-analysis of risk ratios was performed using inverse variance method.  A total of 
44 studies were included in the review with 230,795 participants. The prevalence of baseline 
anemia was 26,514/170,914 (16%).  There was an elevated risk of mortality and MACE with 
anemia compared to no anemia pooled RR 2.39 (2.02-2.83), p<0.001 and RR 1.51 (1.34-
1.71), p<0.001, respectively.  The risk of myocardial infarction and bleeding with anemia 
compared to no anemia was elevated, pooled RR 1.33 (1.07-1.65), p=0.01 and RR 1.97 (1.03-
3.77), p<0.001, respectively.  The risk of mortality per unit incremental decrease in 
hemoglobin(g/dl) was RR 1.19 (1.09-1.30), p<0.001 and the risk of mortality, MACE and re-
infarction per 1 unit incremental decrease in hematocrit(%) was RR 1.07 (1.05-1.10), p=0.04, 
RR 1.09 (1.08-1.10) and RR 1.06 (1.03-1.10), respectively. The prevalence of anemia in 
contemporary cohorts of patients undergoing PCI is significant and is associated with 
significant increases in post procedural mortality, MACE, re-infarction and bleeding. The 
optimal strategy for the management of anemia in such patients remains uncertain. 
Keywords: Percutaneous coronary intervention; anemia; mortality 
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Introduction 
 The prevalence of anemia amongst patients undergoing percutaneous coronary 
interventions (PCI) is reported between 10-23% in randomized controlled trials,1-3 with rates 
>30% reported in observational registries.4,5 Current clinical guidelines fail to offer 
recommendations for its concurrent management in patients undergoing PCI. Patients with 
anemia who undergo PCI are frequently older,5-6 with multiple co-morbidities1,7-12 and more 
extensive and complex coronary disease.11-12 These clinical and procedural characteristics are 
well known to be associated with poorer outcomes post PCI. Many studies previously have 
reported that the presence of baseline anemia is independently associated with mortality5,7,8,13 
and major adverse cardiovascular events (MACE)5,14 and major bleeding complications15 and 
several PCI risk scores have used anemia as important predictors for both mortality16 and 
bleeding outcomes.17 In contrast, other studies suggest that whilst these relationships exists 
for unadjusted data, anemia is no longer associated with increased mortality following 
adjustment for potential confounders14,18-19 To the best of our knowledge, there has not been a 
systematic review or meta-analysis of the prevalence and prognostic impact of anemia in the 
setting of PCI. We have therefore undertaken a meta-analysis to systematically study the 
impact of anemia in patients who have undergone PCI on mortality, MACE, major bleeding 
and re-infarction.  
Methods 
We selected studies of participants who underwent PCI and reported any of the 
following adverse outcomes: mortality, MACE by any definition or combination of (adverse 
cardiovascular events and mortality), re-infarction and bleeding among patients who were 
anemic and non-anemic. We also included studies that evaluated the risk of adverse outcomes 
for incremental increase or decrease in hemoglobin.  
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 A search of MEDLINE and EMBASE was performed on OVID SP on April, 8 2014.  
The exact search strategy is shown in Supplementary Table 1 (online only).  There was no 
restriction on the search based on language and both abstracts and unpublished literature were 
included.  
Three reviewers (C.S.K., A.P. and A.A.) independently screened all titles and 
abstracts for studies potentially meeting the inclusion criteria. The full reports of these studies 
were retrieved, and data were extracted independently by two reviewers (C.S.K. and D.T.). 
Data extracted included study design, participant characteristics, participant inclusion criteria, 
definition of anemia or incremental hemoglobin change, adverse outcomes and follow up. 
Additional data was collected on quality of studies that included ascertainment of anemia, 
ascertainment of outcomes, loss to follow up and use of adjustments for confounding.  
Publication bias was assessed using funnel plots for analyses with >10 studies and no 
evidence of substantial heterogeneity.20 
We used RevMan (version 5.3, Nordic Cochrane Centre, Copenhagen, Denmark) to 
perform random effects meta-analysis using inverse variance methods for pooling risk ratios.  
We assumed similarity between odds ratio and other relative measures such as relative risk, 
rate ratios and hazard ratios because cardiovascular events were rare events.21 We chose to 
pool adjusted results when available and crude results when adjusted results were not 
available.  For datasets with the multiple time points we chose to pool the results of the 
longest time-point (up to 4.5 year interval) in the individual primary analysis.  The I2 statistic 
was used to assess statistical heterogeneity. We performed the primary analysis considering 
unadjusted and adjusted results for anemic and non-anemic patients for the outcomes 
mortality, MACE, re-infarction and bleeding.  Secondary analysis was performed considering 
both the incremental decrease in hemoglobin per unit and incremental decrease in hematocrit 
and the risk of adverse outcomes.  For the main analysis of anemia and risk of mortality, we 
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also performed sensitivity analysis considering only studies that adjusted for baseline 
hemoglobin, renal impairment and the severity of anemia.  Further analysis was performed 
considering the effect of elective or ACS patients on outcomes. 
Results 
 The process of study selection is shown in Figure 1. 44 studiesS1-S44 (Online 
Supplementary Data) were included with a total of 230,795 participants.  The number of 
participants ranged from 100 to 73,067 and the overall prevalence of anemia was 
26,514/170,914 (15.5% (15.3-15.7)) and for individual studies the prevalence ranged from 
3% to 41%. The study design, study dates, country of origin and indications for PCI are 
shown in Table 1.  There were 4 post hoc analyses of randomized controlled trials, 14 
prospective cohort studies, 14 retrospective cohort studies and 12 cohort studies of unclear 
design.  There were 15 studies of patients with STEMI, 1 study of only NSTEMI patients and 
all patients included in the analysis underwent PCI.   
 Supplementary Table 2 (online only) shows the risk of bias table for the included 
studies.  Almost all of the studies specified that blood measurements were taken prior to PCI 
except one study with unclear timing of blood sampling.  A variety of methods were used to 
ascertain adverse outcomes after PCI and loss to follow up was reported in 18 studies. The 
majority of studies reported at least one adjusted analysis except for 5 studies. 
The study definitions of anemia, lengths of follow up and results are shown in Table 2 
and Supplementary Table 3 (online only).  The most frequent definition of anemia was the 
WHO criteria and the mean follow up of the studies ranged from in-hospital events up to 4.5 
years.  The risk of mortality and MACE (as defined by each study in Supplementary Table 4 
(online only)) with anemia compared to no anemia was RR 2.39 (2.02-2.83) (32 studies, 
134,042 participants) (Figure 2) and RR 1.51 (1.34-1.71) (20 studies, 47,552 participants) 
(Figure 3), respectively.  There was a significant difference between the unadjusted and 
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adjusted results for anemia and mortality (p=0.02).  The risk of re-infarction and bleeding 
with anemia compared to no anemia was RR 1.33 (1.07-1.65) (13 studies, 36,316 
participants) (Figure 4) and RR 1.97 (1.03-3.77) (11 studies, 34,388 participants) (Figure 5), 
respectively. A summary of key results are shown in Figure 6. 
 The analysis for incremental decrease in hemoglobin and hematocrit is shown in 
Figure 7.  The risk of mortality for incremental decrease in every 1 unit of hemoglobin (g/dl) 
was RR 1.19 (1.09-1.30) (7 studies, 82,208 participants) and the risk of mortality, MACE and 
re-infarction was RR 1.07 (1.05-1.10) (3 studies, 14,519 participants), RR 1.09 (1.08-1.10) (1 
study, 6,025 participants) and RR 1.06 (1.03-1.10) (1 study, 6,025 participants), respectively. 
 Sensitivity analysis was performed considering the subgroup of studies that had used 
adjustments for baseline hemoglobin or renal impairment or severity of anemia (Figure 8).  
The pooled results of 3 studies that adjusted for baseline hemoglobin showed a significant 
increase in mortality (RR 1.81 (1.62-2.01)). Similarly, a significantly higher mortality was 
observed for studies that adjusted for renal impairment (RR 2.05 (1.69-2.49)).  Kitai et al was 
the only study that considered severity of anemia and showed a dose response relationship; 
mild anemia (>10 g/dL) was associated with RR 1.86 (1.42-2.43) while moderate to severe 
anemia (<10 g/dL) was associated with greater mortality (RR 3.35 (2.52-4.46)). 
Further analyses considering elective cases only, ACS cases only and any PCI cases 
separately are shown in Supplementary Figures 1-4 (online only) and Supplementary Table 5 
(online only).  There were significant increases in mortality, MACE and bleeding outcomes 
for patients with anemia in both the ACS and elective setting in adjusted analyses. However, 
there was only a significant increase in mortality with incremental decrease in hemoglobin in 
elective cases but not ACS.   
Discussion 
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 This meta-analysis of 44 studies including 230,795 patients has shown that the mean 
prevalence of anemia in contemporary PCI is 16% and is independently associated with a 2-
fold increased risk of mortality, MACE events and major bleeding with elevation in risk 
associated with incremental decreases in hemoglobin levels. This increased risk appears to be 
independent of the common causes of anemia such as chronic renal disease or bleeding 
events sustained peri-procedurally, and is of similar magnitude in both the elective and ACS 
setting. The present analysis is the first to systematically study the prognostic impact of 
anemia in contemporary cohorts undergoing PCI. 
 Previous studies report conflicting data regarding the association between anemia and 
clinical outcomes in patients undergoing PCI, with studies reporting both an independent 
association with increased mortality, MACE and major bleeding complications3,5,7-9,13-15 or no 
increase in risk following adjustment for differences in age, comorbidity burden and 
procedural demographics,8,18 or only associated with poorer outcomes in patients with severe 
anemia but not mild or moderate anemia.10 Other studies have suggested that post-procedural 
anemia is independently associated with MACE.19  
 There are a number of biological and clinical reasons why chronic anemia may lead to 
worse clinical outcomes in patients undergoing PCI. Our analysis suggests that anemia is 
independently associated with a two-fold increased risk of major bleeding complications, 
which themselves are independently associated with increased risk of mortality.22 Anemia is 
also independently associated with a 2.5-fold increased risk of stent thrombosis,8 which might 
further contribute to the adverse outcomes reported. Furthermore, patients with anemia are 
less likely to be prescribed dual antiplatelet therapy peri-procedurally3,23 although Pilgrim et 
al. report that the presence of anemia did not influence the choice of peri-procedural 
antithrombotic or antiplatelet regime at the time of hospital discharge post PCI.8 
Contemporary 3rd generation stent platforms require shorter duration DAPT, with current 
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European Society of Cardiology Guidelines advocating only 6 months DAPT for PCI cases 
undertaken electively,24 whilst the LEADERS FREE study that included high bleeding risk 
patients, including those with anemia demonstrated no excess risk in a DES platform with 
mandated DAPT for 1 month compared to bare-metal stents.25 Furthermore, in the study of 
Pilgrim et al,8 patients with hemoglobin <10 g/dl had an overall transfusion rate that was 6.5-
fold higher compared with patients with hemoglobin >12 g/dl (64.2% vs 9.9%, p <0.0001). 
Our previous meta-analysis showed that the receipt of a blood transfusion in the PCI setting 
is independently associated with a 3-fold increase in mortality and MACE, and this risk 
persists even in the absence of major bleeding events.26 Finally anemia may merely be a 
marker of a greater co-morbid in frailer patients, and the statistical models may have been 
affected by incomplete adjustments for confounders such as co-morbid burden or frailty. 
Previous work has shown that co-morbidity burden is significant in patients undergoing PCI 
and is independently associated with adverse shorter and longer-term clinical outcomes.27  
 Whilst our meta-analysis highlights the independent association between the presence 
of anemia and adverse clinical outcomes in the PCI setting, there are no current 
recommended guidelines for the treatment of anemia in this setting and whether there is a 
threshold level of anemia at which treatment should be considered. Previous reports derived 
from the National Cardiovascular Data Registry dataset have reported significant variations 
in the prevalence of transfusion events in hospitals across the United States following PCI, 
with significant differences in hemoglobin threshold that prompts transfusion.28 Furthermore, 
randomized trials have yielded conflicting data regarding optimal treatment of anemia in 
ACS and PCI settings, for example, in the CRIT (conservative versus liberal red cell 
transfusion in acute myocardial infarction) trial, 45 anemic patients with myocardial 
infarction were randomized to either a transfusion arm or a control arm, with worse outcomes 
reported in patients assigned to the transfusion arm (composite endpoint of in-hospital 
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mortality, re-infarction or HF (38% vs 13%; p = 0.046). In contrast, in the MINT pilot study 
of anemic patients undergoing angiography, patients randomized to a liberal blood 
transfusion strategy had lower MACE rates (10.9%) compared to patients randomized to a 
restrictive transfusion strategy (25.5%), with lower 30-day mortality (1.8%) compared with 
restrictive transfusion patients (13.0%) (p = 0.032).29  
Our analysis has limitations. Although our meta-analysis suggests a dose dependent 
association between the presence of anemia and adverse clinical outcomes in PCI, it cannot 
infer causality. Whilst papers included in this analysis have adjusted for differences in 
baseline characteristics, we cannot rule out unmeasured confounders such as frailty or 
chronic disease that are not fully captured by statistical models that may themselves 
contribute to the poorer outcomes observed. Whilst we report that anemia is independently 
associated with major bleeding complications, the studies included in this meta-analysis do 
not differentiate between access and non-access site bleeding complications, which have 
different prognostic impacts.30 Another limitation was that several analyses had at least a 
moderate level of statistical heterogeneity so we performed sensitivity analysis. Finally, our 
analysis does not provide insight as to whether different etiologies of anemia have a 
differential relationship with clinical outcomes. 
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 Figure Legend 
 
 
 
Figure 1: Flow diagram of study selection 
 
Figure 2: Risk of mortality with anemia compared to no anemia 
 
Figure 3: Risk of major adverse cardiovascular events with anemia compared to no anemia 
 
Figure 4: Risk of re-infarction with anemia compared to no anemia 
 
Figure 5: Risk of bleeding with anemia compared to no anemia 
 
Figure 6: A summary of main results 
 
Figure 7: Risk of adverse outcomes by incremental decrease in hemoglobin (Hb) or 
hematocrit (Hct) 
 
Figure 8: Subgroup analysis of risk of mortality with anemia compared to no anemia 
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Online Supplementary Table 4: Definition of MACE 
 
Online Supplementary Table 5: Sensitivity analysis by indication  
 
Online Supplementary Figure 1: Effect of anemia and low hemoglobin on 30-day mortality 
by indication  
 
Online Supplementary Figure 2: Effect of anemia and low hemoglobin on in-hospital 
MACE by indication 
 
Online Supplementary Figure 3: Effect of anemia and low hemoglobin on in-hospital 
myocardial infarction by indication 
 
Online Supplementary Figure 4: Effect of anemia and low hemoglobin on in-hospital 
bleeding by indication 
 
Online Supplementary Data: References to additional studies 
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Table 1: Study design and participant characteristics 
 
Study ID Date/Year Design  Country No. of centers Total no. of participants, no. anemic 
(% anemic) 
Akgul 2013 Dec 2010 to May 2012. Prospective observational study. Turkey. Single 520, 64 (12%) anemic. 
Ali 2004 Jul 2002 to May 2010 Prospective observational study. USA. Unclear. 11,991, 4,815 (40%) anemic. 
Ayhan 2011 Unclear. Retrospective cohort study. Turkey. Single. 2,509, 616 (25%) anemic. 
Bolinska 2011 May to Dec 2005. Retrospective cohort study. Poland. Single. 551, 61 (11%) anemic. 
Catakoglu 2007 Oct 2001 to June 2002. Prospective cohort study. Turkey. Single. 100, 31 (31%) anemic. 
Chi 2012 Unclear. Cohort study. China. Unclear. 1014, 253 (25%) anemic. 
Cho 2011a Nov 2005 to Jun 2009. Retrospective cohort study. South Korea. Single. 739, 152 (21%) anemic. 
Cho 2011b Mar 2006 to Dec 2009 Prospective cohort study. South Korea. Unclear. 2,849, 679 (24%) anemic. 
Dada 2009 Unclear. Cohort study. USA. Unclear. 6,538, 2,159 (33%) anemic. 
Dunbar 2012 Jan 2006 to Apr 2008. Retrospective cohort study. Turkey. Single center. 1,625, 395 (24%) anemic. 
Feldman 2009 2004 to 2005. Cohort study. USA. Single. 2,504, 709 (28%) anemic. 
Greenberg 2010 Jan 2001 to Dec 2007. Prospective cohort study. Israel. Single. 1,042, 208 (20%) anemic. 
Gurm 2004 Unclear. Post hoc analysis of RCT. USA. Multicenter. 6,322, 638 (10%) anemic. 
Hanna 2013 Jan 2007 to Dec 2009. Cohort study. USA. 354 centers. 73,067, 2,417 (3%) anemic. 
Hosseini 2014 Apr 2005 to Sept 2008 Cohort study. Iran. Single. 2,819, 493 (17%) anemic. 
Husemann 2007 Jan 2001 to Dec 2001. Retrospective cohort study. Germany. Single. 709, 128 (18%) anemic. 
Jones 2010 Jan 2004 to Mar 2009. Prospective cohort study. UK. Single. 1657, 331 (20%) anemic. 
Kim 2012 Jan 2004 to Dec 2009. Retrospective cohort study. South Korea. Single. 3,549, 1,321 (37%) anemic. 
Kitai 2013 Jan 2005 to Dec 2007. Retrospective cohort study. Japan. 26 centers. 7,299, 2,209 (30%) anemic. 
Kruk 2010 Feb 2001 to Dec 2004. Prospective cohort study. Poland. Unclear. 1880, 385 (20%) anemic. 
Kurek 2010 Sept 2004 to Dec 2007. Prospective cohort study. Poland. Single center. 1,497, 248 (17%) anemic. 
Liu 2008 Jul 2003 to Sept 2005. Cohort study. China. Single. 3,809, 744 (20%) anemic. 
Liu 2009 Unclear. Cohort study. Unclear. Unclear. 3770. 
Maluenda 2009 2003 to 2007 Retrospective cohort study. USA. Single. 6,025, 210 (3%) anemic. 
Manzano-
Fernandez 2008 
Unclear. Cohort study. Spain. 2 centers. 278, 114 (41%) anemic. 
McKechnie 2004 July 1997 to May 2003. Prospective cohort study. USA. 18 hospitals. 48,851. 
Nikolsky 2004a Unclear. Post hoc analysis of RCT. International. Multicenter. 2,027, 260 (13%) anemic. 
Nikolsky 2004b 1994 to 1999 Prospective cohort study. USA. Single. 6,929, 1,708 (25%) anemic. 
Oduncu 2013 Unclear. Cohort study. Turkey. Single. 2,411, 623 (26%) anemic. 
Ozasa 2012 2005 to 2007 Retrospective cohort study. Japan. Unclear. 5,336, 1,788 (34%) anemic. 
Park 2012 2004 to 2010. Cohort study. South Korea. Unclear. 881, 349 (40%) anemic. 
Poludasu 2009 Jan 2003 to Aug 2005. Retrospective cohort study. USA. Unclear. 715. 
Rathod 2014 Jan 2004 to Aug 2010. Retrospective cohort study. UK. Single. 2,178, 419 (19%) anemic. 
Reinecke 2003 1998 to 1999 Retrospective cohort study. Germany. Single. 689. 
Rodriguez 2013 2007 to 2011. Prospective cohort study. Spain. Single. 759, 226 (30%) anemic. 
Schroder 2013 2004 to 2006. Retrospective cohort study. Germany. Unclear. 2,056. 
Sgura 2010 2002 to 2008. Cohort study. Italy. Single. 673. 
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Shishehbor 2009 Mar 2003 to June 2007. Prospective cohort study. USA. Single. 2,172. 
Tsujita 2010 Unclear. Post hoc analysis of RCT. International. Multicenter. 3,153, 331 (10%) anemic. 
Uchida 2013 Unclear. Cohort study. Japan. Unclear. 337, 59 (18%) anemic. 
Varma 2010 Apr 2003 to Dec 2005. Retrospective cohort study. USA. Unclear. 120. 
Vis 2010 Jan 1997 to Mar 2005. Prospective cohort study. Netherlands. Single. 292. 
Voeltz 2007 Unclear. Post hoc analysis of RCT. International. Multicenter. 6,010, 1,371 (23%)  anemic. 
Vrslovic 2012 Unclear. Prospective cohort study. Croatia. Single. 543. 
PPCI=primary percutaneous coronary intervention, PCI=percutaneous coronary intervention, STEMI=ST elevated myocardial infarction, RCT=randomized controlled trial. 
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Table 2: Study results 
Study ID Definition of anemia Follow up 
(mo) 
Results 
Hb (mg/dL) Hct (%) 
Akgul 2013 <13(M)<12(F) - 6 Odds of cardiovascular mortality with anemia vs no anemia: aOR 3.9 (1.52-10.2). 
Ali 2004 <13(M)<12(F) - 31 Odds of long term mortality with anemia: aOR: 1.8 (1.6-2.0). In-hospital major bleeding: aOR: 3.3 (2.3-4.6). 
Ayhan 2011 <13(M)<12(F) - In-hospital Odds of long term cardiovascular mortality with anemia vs no anemia: aOR 2.2 (1.2-4.0). 
Bolinska 2011 <13(M)<12(F) - In-hospital Odds of death or cardiovascular complication with incremental Hb: aOR 0.89 (0.754-1.051). 
Catakoglu 2007 - <39%(M)<36%(F) 12 Odds of nonfatal coronary events with anemia vs no anemia: aOR 2.507 (1.379-4.555). 
Chi 2012 <13(M)<12(F) - 17 Risk of long term mortality with anemia vs no anemia: RR 3.293 (1.431-7.578). 
Cho 2011a <13(M)<12(F) - 6 See crude results in Supplementary Material. 
Cho 2011b <13(M)<12(F) - 24 Risk of mortality with anemia vs no anemia: aHR 1.52 (0.90-2.56). MACE: aHR 1.78 (1.14-2.78). 
Dada 2009 <13(M)<12(F) - 9 Odds of in-hospital mortality with anemia vs no anemia: OR 2.87(1.58-6.23). 9 month mortality OR 1.46(1.07-1.99).  
Dunbar 2012 <13(M)<12(F) - In-hospital Odds of in-hospital mortality per 1 g/dl decrease in Hb: aOR 1.28 (1.01-1.63). 
Feldman 2009 ≤12 - 25 See crude results in Supplementary Material. 
Greenberg 2010 - <39%(M)<36%(F) 12 Odds of 1 month mortality with anemia vs no anemia: OR 3.5 (1.6-7.5). 
Gurm 2004 - <35%, 35-40% 36 Risk of 3 year mortality per % of continuous hematocrit: aHR 0.953 (0.930-0.977). 
Hanna 2013 <10, 10-12 - In-hospital Odds of death per 1 g/dl decrease in Hb <15 g/dl: aOR 1.07 (1.02-1.11). 
Hosseini 2014 <13(M)<12(F) - 12 MACE with anemia mild aHR 1.249(0.652-2.39) moderate aHR 1.462(0.584-3.66) severe aHR 4.623(1.642-13.021). 
Husemann 2007 <13(M)<12(F) - "Long term" Risk of long term mortality per unit increase in  Hb: HR 0.711 (0.616-0.819). 
Jones 2010 <13(M)<12(F) - 36 Odds of 3 year mortality with anemia vs no anemia: aOR 2.4 (1.1-3.7). 
Kim 2012 <13(M)<12(F) - 25 Risk with anemia: MACE aHR 1.479(1.025-2.134), death aHR 1.943(1.241-3.043), MI aHR 1.182(0.476-2.936).  
Kitai 2013 <13(M)<12(F) - 36 See results in Supplementary Material for mild/moderate-severe anemia. 
Kruk 2010 - <39%(M)<36%(F) In-hospital Anemia: death HR 2.03(1.19-3.46) HF HR 1.09(0.79-1.51) death/HF HR 1.34(0.98-1.82) bleed HR 1.67(1.12-2.45) 
Kurek 2010 <13(M)<12(F) - 19 Risk of 1 year outcomes with anemia: death aHR1.31(1.14-1.48) MACE aHR1.14(1.03-1.25).  See Supplementary Material. 
Liu 2008 <13(M)<12(F) - Unclear Risk of mortality with anemia: aRR 2.216 (1.019-4.428). 
Liu 2009 - - Unclear Risk of long term mortality and Hb: HR 0.952 (0.921-0.984). 
Maluenda 2009 - - 12 Risk with incremental hematocrit: death HR 0.92(0.91-0.93), MI HR 0.94(0.91-0.97), death/MI HR 0.92(0.91-0.93). 
Manzano 2008 <13(M)<12(F)  19 Risk of major bleed with anemia: aHR 2.15 (1.08-4.30). 
McKechnie 2004 <13(M)<12(F)  In-hospital Anemia: death OR 2.29(1.79-2.92) MACE OR 1.2(1.05-1.34) ↓Hb: death (M) aOR 1.21(1.14-1.28), (F) aOR 1.05(0.97-1.14). 
Nikolsky 2004a - <39%(M)<36%(F) 12 Risk of outcome with anemia: in-hospital mortality: aHR 3.26 (1.01-10.52), 1 year mortality aHR 2.38 (1.18-4.81). 
Nikolsky 2004b -  <39%(M)<36%(F) 12 Odds of 1 year mortality with anemia vs no anemia: aOR 1.88 (1.46-2.43). 
Oduncu 2013 <13(M)<12(F) - 48 Risk of MACE with anemia vs no anemia: aHR 3.12 (1.15-6.59). 
Ozasa 2012 <13(M)<12(F) - Unclear Risk of mortality with anemia vs no anemia aHR 1.96 (1.49-2.58) and cardiac mortality: aHR 1.36 (0.90-2.06). 
Park 2012 <13(M)<12(F) - 24 Odds of 2 year mortality with anemia vs no anemia: OR 3.78 (2.19-6.52). 
Poludasu 2009 <13(M)<12(F) - 38 See crude results in Supplementary Material. 
Rathod 2014 <13(M)<12(F) - 36 Risk of mortality with anemia vs no anemia: propensity score matched HR 1.14 (0.52-2.49). 
Reinecke 2003 <13 - 23 Risk of death with incremental increase in Hb HR 0.68 (0.59-0.78) and anemia vs no anemia HR 4.09 (1.52-11.05). 
Rodriguez 2013 <13(M)<12(F)  27 Risk of mortality with anemia vs no anemia: aHR 2.1 (1.1-4.1). 
Schroder 2013 - - 32 Risk of mortality with incremental increase in Hb: aHR 0.784 (0.62-0.991). 
Sgura 2010 <13(M)<12(F) - 30 See crude results in Supplementary Material. 
Shishehbor 2009 - <40%(M)<36%(F) 54 Risk of mortality with incremental increase in hematocrit aHR 0.93 (0.91-0.96).  
Tsujita 2010 - <39%(M)<36%(F) 12 Risk of with anemia vs no anemia: 1 year mortality aHR 1.98 (1.05-3.73), major bleeding: aHR 2.15 (1.43-3.24). 
Uchida 2013 <13(M)<12(F) - Unclear Risk of adverse events with anemia vs no anemia: aHR 2.58 (1.01-6.60). 
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Varma 2010 <13(M)<12(F) - 30 See crude results in Supplementary Material. 
Vis 2010 <13(M)<12(F) - 12 Odds of 1 year mortality with incremental Hb: aOR 0.992 (0.992-1.423).  
Voeltz 2007 <13(M)<12(F) - 12 Risk of 1 year mortality with anemia vs no anemia: aHR 1.84 (1.22-2.78). 
Vrsalovic 2012 <13(M)<12(F) - 1 Odds of 30 day mortality with anemia vs no anemia: aOR 2.69 (1.24-5.86). 
M=male, F=female, Hb=hemoglobin, HF=heart failure aHR=adjusted hazard ratio. aOR=adjusted odds ratio. aRR=adjusted relative risk. 
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